Buy Afinitor today! Finally Afinitor is availble for purchase at an affordable  price to patients with metatstatic kidney cancer, renal cell carcinoma! (RCC) 

                                

    

Afinitor is a MTOR inhibitor,it's a targeted therapy, that significantly delays progression of metastatic kidney cancer in patients whose disease has worsened despite treatment, according to results of a phase III trial. Unlike Temsirolimus, which is administered parenterally (intravenous infusion) every week, Afinitor is administered orally as a daily set of tablets!

MTOR pathway is critical for cell growth and angiogenesis. It is considered to be a major regulator of cell growth, whereby nutrients and growth factors turn on signals to promote sub & vascular growth. Renal cancer growth and progression are dependent on the mTORpathway.

RECORD-1 TRIAL  a phase 3, randomized, multicenter trial that compared Afinitor (10 mg orally daily) and placebo. A total of 272 patients were treated by Afinitor and 138 by placebo. The 2 study arms were well balanced with regard to patient's baseline characteristics.

Results:  Only 31% of patients had progressive disease on Afinitor compared with 73% of patients on the placebo arm.  The median overall survival for Afinitor-treated patients has not yet been reached (over 18 month), compared to the median survival for patients on the placebo arm that was 8.8 months ! On February 2008, an independent monitoring committee stopped the phase III trial after interim results were positive and allowed researchers to offer Afinitor to the patients receiving placebo

Expert's opinion (lead researcher Robert Motzer, MD, an attending physician at Memorial Sloan-Kettering Cancer Center in New York.) 

"This study has given us a new and clearly useful tool for treating renal cell tumors,  Afinitor is an important step forward in terms of disease management and quality of life for patients living with this disease,  

We found the safety was acceptable with Afinitor and we also looked at quality of life studies and there was no worsening in quality of life compared to placebo treatment, Dr. Motzer said.  

For almost 20 years, we made no headway in the management of advanced kidney cancer, 

Recently, the identification of several new angiogenesis-targeted agents has provided us with new treatment options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, Afinitor could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of treatment advances.

"Afinitor is the first agent shown to be effective in RCC patients who have failed previous treatment with sunitinib, sorafenib, or both agents"

"Pending FDA approval, Afinitor should become standard of care for this patient population"

             Buy Afinitor call us toll free 1-866-474-2289

Finally Afinitor is available for the treatment of  metastatic RCC !

Here is Where You can Buy Afinitor the metastatic kidney cancer treatment, renal cancer carcinoma.

Afinitor is a mTOR (mammalian target of rapamycin) inhibitor. The mTOR pathway is critical for cell rapid growth and angiogenesis. It is considered to be a major regulator of cell rapid growth, whereby nutrients and rapid growth factors turn on signals to promote sub rapid growth in angiogenesis. Renal cancer rapid growth and progression are dependent on the mTOR pathway. Unlike temsirolimus, which is administered parenterally every week, Afinitor is administered orally as a daily set of tablets.

 

RECORD-1 TRIAL phase 3, randomized, multicenter trial that compared Afinitor (10 mg orally daily) and placebo 2:1 in a double-blind fashion. The key eligibility criteria were metastatic RCC patients that had progressive disease on or within 6 months of treatment with the VEGF receptor tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, or both. Overall, 410 patients were randomized. A total of 272 patients were randomized to Afinitor and 138 to placebo. The 2 study arms were well balanced with regard to baseline characteristics. The median patient age was about 60 years, and about two thirds had Karnofsky performance status = 90. About 90% of patients had metastatic disease at 2 or more sites, predominantly in the lungs. 95% had undergone nephrectomy, and about 30% had prior radiation therapy.Results: an independent data monitoring committee found that the interim results of the study showed significantly better PFS in patients with advanced RCC who received Afinitor compared with placebo and recommended termination of the study in February 2008. Only 31% of patients had progressive disease on Afinitor compared with 73% of patients on the placebo arm. Overall survival by treatment was presented at the recent ASCO meeting.^[4] The median overall survival for Afinitor-treated patients has not yet been reached (over 18 month), compared to the median survival for patients on the placeboarm that was 8.8 months. The hazard ratio was 0.83, and the P value was not statistically significant. We are quite certain that the patients who had been on placebo and crossed over to Afinitor confound the survival endpoint: 81% of those with progression of disease on placebo successfully crossed over to Afinitor. Thus, the indicator for clinical benefit and activity of Afinitor will be PFS. The trial was, in fact, designed to ensure that all patients had access to Afinitor. Adverse events Stomatitis 40% of patients in the Afinitor group vs. 8% in the placebo group, rash 25% vs. 4%, and fatigue 20% vs. 16% were the most commonly reported adverse events, but were mostly mild or moderate in severity. Pneumonitis (any grade) was detected in 22 (8%) patients in the Afinitor group, of whom eight had pneumonitis of grade 3 severity.

 

 

Editor's Note:

Afinitor is intended for Metastatic RCC patients. FDA approval is pending and expected in a about a year from today, Like other patients around the world US patients suffering from metastatic RCC deserve access to this novel treatment option!   IsraMeds offers your patients immediate access (3 day shipping) after receiving a prescription and payment. 

Afinitor tablets are made by Novartis Switzerland.

Treatment with Afinitor cost 250$per day which is 10% less then other TKI (Sutent, Nexavar) 275-300$per day.

Our Online Pharmacy is Where you can buy Afinitor a treatment for Metastatic Kidney Cancer.